ArticleClinical rheumatology2017
Clinical, biochemical, and radiological characterization of the calcinosis in a cohort of Mexican patients with systemic sclerosis.
Article in Clinical rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06155578 (Randomized Placebo-controlled Trial of the Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis.), which is not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Placebo-controlled Trial of the Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Dualities of the vitamin D in systemic sclerosis: a systematic literature review.Advances in rheumatology (London, England) · 2021Pooled it
- Role of Vitamin D in Systemic Sclerosis: A Systematic Literature Review.Journal of immunology research · 2021Pooled it
- Ultrasound characterization of cutaneous ulcers in systemic sclerosis.Clinical rheumatology · 2018Trial
- Outcome Measures in Dystrophic Calcinosis Cutis: A Systematic Review.JID innovations : skin science from molecules to population health · 2025Review
- Wound, pressure ulcer, and burn guidelines (2023)-4: Guidelines for the management of connective tissue disease/vasculitis-associated skin ulcers, third edition.The Journal of dermatology · 2025Article
- Article
- Unraveling the Pathogenesis of Calcinosis in Systemic Sclerosis: A Molecular and Clinical Insight.International journal of molecular sciences · 2024Review
- Treatment of Calcinosis in Dermatomyositis-Case Report and Review.Journal of clinical medicine · 2024Article
- Calcinosis Prevalence in Autoimmune Connective Tissue Diseases-A Retrospective Study.Journal of clinical medicine · 2024Article
- Calcinosis in Rheumatic Disease Is Still an Unmet Need: A Retrospective Single-Center Study.Diagnostics (Basel, Switzerland) · 2024Article
- [Systemic sclerosis].Dermatologie (Heidelberg, Germany) · 2024Review
- BMP-4 and fetuin A in systemic sclerosis patients with or without calcinosis.Frontiers in immunology · 2024Observational
- Cumulative disease damage and anti-PM/Scl antibodies are associated with a heavy burden of calcinosis in systemic sclerosis.Rheumatology (Oxford, England) · 2023Review
- Assessment of calcinosis in Portuguese patients with systemic sclerosis - a multicenter study.Clinical rheumatology · 2023Article
- Review
- Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics.Journal of clinical medicine · 2022Review
- Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?Journal of scleroderma and related disorders · 2022Review
- A narrative review of imaging in calcinosis associated with systemic sclerosis.Clinical rheumatology · 2021Review
- The impact of skin calcinosis on digital ulcers in patients with SSc: clinical and prognostic stratification using the "wound bed score".International wound journal · 2020Article
- Efficacy of intralesional sodium thiosulfate for the treatment of dystrophic calcinosis cutis: A double-blind, placebo-controlled pilot study.JAAD international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcinosis is a frequent complication of systemic sclerosis (SSc) that is usually located in extremities but may occur across the board. The aim of our study was to identify and quantify the distribution of calcinosis in a cohort of Mexican patients with SSc and its association with clinical features and autoantibodies. A cohort of patients with SSc (2013 ACR/EULAR criteria), classified in diffuse cutaneous (dcSSc) and limited cutaneous (lcSSc) (Le Roy criteria), was studied. For their analysis, patients were allocated into those with and without calcinosis (clinical and/or radiological). The evaluation included the modified Rodnan scale for skin and Medsger disease severity scale (DSS). Calcium, phosphorus, vitamin D, and parathyroid hormone (PTH) and antinuclear antibodies and extractable nuclear antigens were determined in serum. A total of 109 patients were included, 41 (37 %) with and 68 (63 %) without calcinosis. Calcinosis was more frequent in patients with dcSSc (55 vs 27 %). In total, we identified 354 sites with calcinosis and mean per patient of 12.0 ± 9.1; the most common sites affected were the hands (83 %), proximal upper extremity (27 %), and proximal lower extremity (22 %). Patients with calcinosis had a higher score of Rodnan scale, Mesdger DSS, and frequency of anti-nucleolar and anti-Scl-70 antibodies compared to those without calcinosis. Abnormal PTH elevation was found in 35 % of patients with calcinosis and 23 % without it. The prevalence of calcinosis is high in Mexican patients with SSc, especially in diffuse variety, and is associated with increased severity of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.